Cortés, J., Dieras, V., Ro, J., Barriere, J., Bachelot, T., Hurvitz, S., Le Rhun, E., Espié, M., Kim, S., Schneeweiss, A., Sohn, J. H., Nabholtz, J., Kellokumpu-Lehtinen, P., Taguchi, J., Piacentini, F., Ciruelos, E., Bono, P., Ould-Kaci, M., Roux, F., & Joensuu, H. (2015). afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial. Lancet oncology, 16(16), 1700–1710. http://access.bl.uk/ark:/81055/vdc_100029474807.0x000020